What the research found

Enlicitide (Lipfendra) is an oral small-molecule PCSK9 inhibitor recently approved by the FDA to lower LDL cholesterol. In the pivotal trial, it achieved approximately 56% placebo-adjusted LDL reduction in patients already on statin therapy—97% of whom had baseline LDL around 96 mg/dL despite treatment. The drug works by binding circulating PCSK9 and preventing it from degrading LDL receptors on liver cells, preserving the liver's capacity to clear LDL particles from the bloodstream.

The key distinction is mechanistic: enlicitide doesn't directly remove plaque or alter existing atherosclerosis. Instead, it modulates the rate at which LDL particles enter circulation and encounter artery walls. This represents a different intervention point than statins (which reduce cholesterol synthesis) or ezetimibe (which blocks intestinal absorption), making it potentially compatible with other lipid-lowering agents.

Why it matters for you

If you're tracking lipid biomarkers and your LDL or ApoB remains elevated despite statin therapy, enlicitide offers another layer of reduction without a subcutaneous injection—a practical advantage over earlier PCSK9 inhibitors like evolocumab or alirocumab. This matters if adherence to injectables has been a friction point or if you prefer oral dosing.

However, the critical caveat: FDA approval is based on lowering a blood marker, not on preventing heart attacks or extending life. Merck's own regulatory announcement notes that cardiovascular outcomes data do not yet exist. You should understand that 56% LDL reduction is impressive on paper, but translating that to reduced cardiac risk still requires ongoing trial evidence. For most MyKine users in good health with normal lipids, this is not relevant. For those with familial hypercholesterolaemia or persistent LDL elevation despite multiple agents, it's worth discussing with a cardiologist—but as a risk reduction tool, not a disease cure.

The drug also carries practical barriers: cost, insurance access, and whether it's prescribed at all outside specialist lipid clinics remain open questions.

Caveats

• Cardiovascular outcomes trial is ongoing; LDL reduction alone does not prove benefit for heart attack or stroke prevention
• Trial population was overwhelmingly on background statin therapy; unclear efficacy as monotherapy or in treatment-naïve patients
• No head-to-head comparison with injectable PCSK9 inhibitors provided in the source
• Insurance and access barriers not addressed in regulatory data
• Long-term safety and persistence of effect unknown at this stage